Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2610 - Potential impact of avelumab+axitinib (A+Ax) on tumor size (TS) compared with historical data of sunitinib (S) as evaluated by a modeling and simulation (MS) approach

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Immunotherapy;  Renal Cell Cancer

Presenters

Jenny Zheng

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

J. Zheng1, A. Chang2, J. Larkin3, R.J. Motzer4, M. Amantea5, C. Bello6, D. Pavlov7, M. Geraldes8, M. Martignoni9, A. Di Pietro9, G. Andrews10

Author affiliations

  • 1 Pharmacometrics, Global Product Development, Pfizer Inc., 19426 - Collegeville/US
  • 2 Clinical Pharmacology, Pfizer Inc., San Diego/US
  • 3 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 4 Medical Oncology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 5 Pharmacometrics, Pfizer Inc., San Diego/US
  • 6 Medical Oncology, Pfizer Inc., 10017 - New York/US
  • 7 Biostatistics, Pfizer Inc., San Diego/US
  • 8 Biostatistics, Pfizer Inc., New York/US
  • 9 Immuno-oncology, Pfizer Inc., 20152 - Milan/IT
  • 10 Immuno-oncology, Pfizer Inc., 92121 - San Diego/US
More

Resources

Abstract 2610

Background

Combining an immune checkpoint inhibitor (A) with a targeted VEGF antiangiogenic agent (Ax) may leverage complementary mechanisms of action for treatment of metastatic renal cell carcinoma (mRCC). JAVELIN Renal 100 is a phase (Ph) 1b trial evaluating the clinical activity and safety of A+Ax in treatment-naïve patients (pts) with mRCC. An early evaluation of the effect of A+Ax on TS, i.e. sum of diameters for target lesions, compared to historical S, the standard of care1, can inform on decisions for future drug development for A+Ax. Claret et al. have shown that a greater early TS reduction at week 8 of treatment (TR8) is correlated with a longer progression free survival time in trials of 1st line treatment of mRCC2. The objective of this analysis is to apply MS methodology to data from JAVELIN Renal 100 to evaluate the potential effect of A+Ax on TS as compared to historical S data.

Methods

A tumor dynamic model3 was applied to the longitudinal TS data obtained from the Ph1b study of A+Ax and from the historical Ph3 trial of S. The model includes 3 parameters representing the rate of tumor growth (KL), the rate of drug effect in reducing tumor size (KD), and the rate of the loss of drug effect (DM). The TR8 for each patient can be derived from the model. A larger KD, smaller DM, and TR8 suggested a greater effect. The parameters and TR8 from the two treatments are estimated and compared using ANOVA.

Results

The summaries of the model parameters, TR8, and p-value of ANOVA analysis are presented in the Table below:Table:

882P

Avelumab + axitinib (N = 53) (mean ± SD)Sunitinib alone (N = 349) (mean ± SD)p-value
TR80.757 ± 0.1620.808 ± 0.1320.012
KL (1/week)0.011 ± 0.0140.009 ± 0.0120.398
KD (1/week)0.065 ± 0.0270.054 ± 0.0340.021
DM (1/week)0.081 ± 0.0240.095 ± 0.0490.040

A+Ax resulted in a greater effect on TR8, a faster tumor size reduction and a more sustained effect than S.

Conclusions

MS is an effective tool to inform drug development. These results suggest that A+Ax results in a greater TS reduction than S, supporting further investigation of A+Ax vs S in the JAVELIN 101 randomized Ph3 trial. References: 1. Motzer R et al NEJM (2007) 356:115 2. Claret L et al Cancer Chemother Pharmacol (2016) 78:605 3. Claret L et al PAGE 2012 Abstr 2328.

Clinical trial identification

NCT02493751 B9991002

Legal entity responsible for the study

Merck KGaA, Darmstadt, Germany; Pfizer Inc, New York, NY, USA.

Funding

Pfizer Inc., New York, NY, USA and Merck KGaA, Darmstadt, Germany.

Disclosure

J. Zheng, A. Chang, D. Pavlov: Employee of Pfizer Inc. and hold Pfizer Inc. stock. J. Larkin: Consultant role for Eisai, Bristol-Myers Squib, MSD, GlaxoSmithKline, Kymab, Pfizer, Novartis, Roche/Genentech, Secarna, Pierre Fabre, EUSA Pharma. Received grants from Bristol-Myers Squib, MSD, Novartis, Pfizer. Honoraria from Bristol-Myers Squib, MSD, Novartis, Pfizer, Eisai, GlaxoSmithKline, Roche. R.J. Motzer: Received research funding from Pfizer, Eisai, Exelixis, Novartis, Bristol-Myers Squib. Consultant role for Pfizer, Eisai, Exelixis, Novartis. M. Amantea, C. Bello, M. Geraldes, M. Martignoni, A. Di Pietro, G. Andrews: Employee of Pfizer Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.